BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · IEX Real-Time Price · USD
1.965
-0.105 (-5.07%)
At close: Jul 26, 2024, 3:59 PM
1.940
-0.025 (-1.27%)
After-hours: Jul 26, 2024, 4:10 PM EDT
BeyondSpring Revenue
In the year 2023, BeyondSpring had annual revenue of $1.75M with 29.61% growth. BeyondSpring had revenue of $876.00K in the half year ending December 31, 2023, with 29.78% growth.
Revenue (ttm)
$1.75M
Revenue Growth
+29.61%
P/S Ratio
46.09
Revenue / Employee
$48,639
Employees
36
Market Cap
79.19M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 281.06M |
SCYNEXIS | 140.39M |
Hyperfine | 11.69M |
Ikena Oncology | 3.85M |
Monogram Orthopaedics | 365.00K |
BYSI News
- 2 months ago - BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire
- 3 months ago - BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire
- 3 months ago - BeyondSpring Files 2023 Annual Report on Form 20-F - GlobeNewsWire
- 3 months ago - BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results - GlobeNewsWire
- 4 months ago - BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer - GlobeNewsWire
- 7 months ago - BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K - GlobeNewsWire
- 7 months ago - BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements - GlobeNewsWire
- 9 months ago - BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor - GlobeNewsWire